These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 3468564

  • 21. Interactions of bupranolol with the polymorphic debrisoquine/sparteine monooxygenase (CYP2D6).
    Pressacco J, Muller R, Kalow W.
    Eur J Clin Pharmacol; 1993; 45(3):261-4. PubMed ID: 8276051
    [Abstract] [Full Text] [Related]

  • 22. Lack association between schizophrenia and the CYP2D6 gene polymorphisms.
    Pirmohamed M, Wild MJ, Kitteringham NR, O'Brien K, Buchan IE, Back DJ, Park BK.
    Am J Med Genet; 1996 Apr 09; 67(2):236-7. PubMed ID: 8723057
    [No Abstract] [Full Text] [Related]

  • 23. [The excessive activity of cytochrome P450 system in ALS--the metabolic ratio of sparteine].
    Kaneko K, Atsumi T, Miyataka T.
    Rinsho Shinkeigaku; 1989 Oct 09; 29(10):1251-5. PubMed ID: 2605831
    [Abstract] [Full Text] [Related]

  • 24. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.
    Fromm MF, Hofmann U, Griese EU, Mikus G.
    Clin Pharmacol Ther; 1995 Oct 09; 58(4):374-82. PubMed ID: 7586928
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Susceptibility to astrocytoma and meningioma: influence of allelism at glutathione S-transferase (GSTT1 and GSTM1) and cytochrome P-450 (CYP2D6) loci.
    Elexpuru-Camiruaga J, Buxton N, Kandula V, Dias PS, Campbell D, McIntosh J, Broome J, Jones P, Inskip A, Alldersea J.
    Cancer Res; 1995 Oct 01; 55(19):4237-9. PubMed ID: 7671227
    [Abstract] [Full Text] [Related]

  • 30. Clinically significant cytochrome P-450 drug interactions--a comment.
    Ford NF, Sonnichsen DS.
    Pharmacotherapy; 1998 Oct 01; 18(4):890-1; discussion 892-3. PubMed ID: 9692671
    [No Abstract] [Full Text] [Related]

  • 31. Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians.
    Lennard MS, Iyun AO, Jackson PR, Tucker GT, Woods HF.
    Pharmacogenetics; 1992 Apr 01; 2(2):89-92. PubMed ID: 1302046
    [Abstract] [Full Text] [Related]

  • 32. Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease.
    Bordet R, Broly F, Destée A, Libersa C.
    Adv Neurol; 1996 Apr 01; 69():97-100. PubMed ID: 8615190
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group.
    Gram LF, Brøsen K.
    Br J Clin Pharmacol; 1993 Jun 01; 35(6):649-52. PubMed ID: 8329293
    [Abstract] [Full Text] [Related]

  • 40. [Clinical aspects of the polymorphism of oxidation phenotype].
    Mrozikiewicz PM.
    Pol Tyg Lek; 1993 Jun 01; 47(27-28):608-10. PubMed ID: 1488339
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.